Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone908-617-1309
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$96.43 million
Profitability
Miscellaneous
Employees290
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work?
Melinta Therapeutics's stock reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics Inc (NASDAQ:MLNT) posted its earnings results on Tuesday, August, 7th. The biotechnology company reported ($6.90) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($5.70) by $1.20. The biotechnology company earned $12.02 million during the quarter, compared to the consensus estimate of $12.06 million. Melinta Therapeutics had a negative net margin of 163.01% and a negative return on equity of 60.83%. View Melinta Therapeutics' Earnings History.
When is Melinta Therapeutics' next earnings date?
What price target have analysts set for MLNT?
7 brokers have issued 1 year price objectives for Melinta Therapeutics' shares. Their forecasts range from $40.00 to $75.00. On average, they anticipate Melinta Therapeutics' stock price to reach $62.9167 in the next twelve months. This suggests a possible upside of 1,564.5% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.
What is the consensus analysts' recommendation for Melinta Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.
Has Melinta Therapeutics been receiving favorable news coverage?
Media headlines about MLNT stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Melinta Therapeutics earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.
Are investors shorting Melinta Therapeutics?
Melinta Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totalling 2,245,682 shares, an increase of 90.6% from the January 31st total of 1,178,376 shares. Based on an average trading volume of 3,554,089 shares, the short-interest ratio is currently 0.6 days. Approximately 31.2% of the shares of the company are sold short. View Melinta Therapeutics' Current Options Chain.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include Aratana Therapeutics (PETX), Menlo Therapeutics (MNLO), Galmed Pharmaceuticals (GLMD), BELLUS Health (BLUSF), Nature's Sunshine Products (NATR), Axovant Sciences (AXON), Ocular Therapeutix (OCUL), PhaseBio Pharmaceuticals (PHAS), Humanigen (HGEN), ProMetic Life Sciences (PFSCF), Bellicum Pharmaceuticals (BLCM), Spring Bank Pharmaceuticals (SBPH), Trevena (TRVN), Northwest Biotherapeutics (NWBO) and Neos Therapeutics (NEOS).
What other stocks do shareholders of Melinta Therapeutics own?
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)
- Mr. John H. Johnson, CEO & Director (Age 61)
- Dr. Thomas A. Steitz, Co-Founder
- Dr. Peter B. Moore Ph.D., Co-Founder
- Dr. William L. Jorgensen Ph.D., Co-Founder
Who are Melinta Therapeutics' major shareholders?
Melinta Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.52%), First Manhattan Co. (1.69%), Dimensional Fund Advisors LP (1.38%), Dimensional Fund Advisors LP (6.90%), Millennium Management LLC (1.07%) and Fosun International Ltd (0.88%). Company insiders that own Melinta Therapeutics stock include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Which major investors are selling Melinta Therapeutics stock?
Which major investors are buying Melinta Therapeutics stock?
MLNT stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Assenagon Asset Management S.A., Boenning & Scattergood Inc., BlackRock Inc., Condor Capital Management, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.
How do I buy shares of Melinta Therapeutics?
Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of MLNT stock can currently be purchased for approximately $3.78.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $42.45 million and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.
What is Melinta Therapeutics' official website?
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07963. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
